Atlas Arteria (ALX AU): The IE Says NOT Fair & Reasonable. All Eyes On Skyway's Put Option
Intriguing situation. The 45% acceptance threshold remains doable despite a hostile situation and considerable IE/IBC pushback. If not in, I'd be picking up shares on weakness.
Tuas (TUA AU): Even IF In Breach, This Is A Buy
Despite an uncertain backdrop, Tuas' share price appears unduly beaten up here. Yes - absent the M1 merger, it remains Singapore's budget operator. But this is still a short-term buy.
Atlas Arteria (ALX AU): IFM Makes Its Move
Atlas does boast low risk, stable yielding, toll road assets. And there are little to no viable options, in size, in Australia's listed infrastructure space. Atlas and IFM don't see to eye to eye - a rejection of the Offer is conceivable
Qube (QUB AU): 16th June Vote On MAM's
SchemeTrading tight at a 2.7%/10.9% gross/annualised spread - net of the intrerim divvy - even when factoring in franking credits for those who can take advantage; and noting ACCC may still raise a SOI.
ENN Energy (2688 HK) Is A Buy
There is material upside to ENN Energy shares here. Plus the FY25 divi of HK$2.35/share should be added. The implied discount for ENN NG's Hs is unrealistic. A share borrow is available.
CKK (1 HK): "New And Perhaps Unforeseen Challenges"
At a ~53% discount to NAV and a forward P/B of 0.40x, CKH is inexpensive. Near term, expect CKH to drift sideways. Longer-term, this is a buy. Overhangs include ongoing geopolitical and regulatory scrutiny; and ME instability
BlueScope (BSL AU): SGH And SDI's Latest NBIO - What Say You AusSuper?
Revised terms are close to SDI's NBIO last year, which was rejected. BlueScope has zero net debt. The USA ops are undervalued. And structurally/politically moated. AustralianSuper should reject terms.